ALS therapeutics landscape projects growth through 2035
An industry analysis values the global ALS therapeutics market at roughly USD 812 million in 2024, projecting growth to about USD 1,964 million by 2035 at an 11.5% CAGR. The report emphasizes disease‑modifying strategies—antisense oligonucleotides, gene therapies and biologics—profiles established and emerging players (Alnylam, Biogen, Ionis, CRISPR Therapeutics, Cytokinetics, Amylyx, among others), and flags clinical complexity and ALS rarity as key development challenges while calling for collaboration across biopharma and regulators.
Why it mattersAntisense oligonucleotide and gene therapy advances suggest investors should prioritize ASO-enabled platforms for ALS programs.